ARHGEF10

Across TCGA pan-cancer cohorts, ARHGEF10 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of ARHGEF10’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ARHGEF10 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARHGEF10 is over-expressed in tumor, although a few such as BLCA and THCA show the opposite, repressed pattern.

KIRC, KIRP, and BLCA are the cancer types where ARHGEF10 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF10 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+1.090	<.001	11	view →
KIRP	All	II,III,IV	+0.873	<.001	11	view →
BLCA	Male	All	−1.187	<.001	8	view →
THCA	All	II,III,IV	−0.605	<.001	8	view →
COAD	All	All	+0.519	<.001	8	view →
LUSC	Female	II,III,IV	−2.238	<.001	7	view →
LUAD	Female	All	−1.094	<.001	7	view →
HNSC	Female	III,IV	+1.144	.003	6	view →
BRCA	All	All	−0.889	<.001	6	view →
KICH	Female	All	−1.426	<.001	5	view →
LIHC	All	All	+0.349	<.001	5	view →
CHOL	Male	All	+2.496	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

ARHGEF10–KIRC

Open the KIRC breakdown →